Evaxion Reports Positive Preclinical Data for AML Vaccine EVX-04
EVAX sits 76% above its 52-week low of $2.07 on light trading volume (0.3× avg).
Summary
Evaxion announced strong preclinical results for its EVX-04 vaccine candidate for acute myeloid leukemia, showing successful immune activation and targeted cell-killing.
Key Events · Product Development and Regulatory · EVAX
-
Positive Preclinical Data for EVX-04
New data shows EVX-04, an off-the-shelf AML vaccine, is successfully expressed and secreted in human cells, enabling immune recognition and activation.
-
Targeted Immune Response
EVX-04 antigens drive specific immune responses in both mice and human cells, inducing targeted cell-killing across different immune profiles.
-
Presentation at EHA 2026 Congress
The detailed preclinical data will be presented at the European Hematology Association (EHA) 2026 Congress on June 13, 2026.
-
Advancing Towards Clinical Testing
The company is preparing the regulatory filing for clinical testing of EVX-04, which targets non-conventional endogenous retrovirus (ERV) tumor antigens.
Analysis · EVAX · Life Sciences
This filing details positive preclinical data for Evaxion's off-the-shelf acute myeloid leukemia (AML) vaccine candidate, EVX-04. The data demonstrates successful expression, immune activation, and targeted cell-killing, supporting its potential as a new therapeutic option for AML patients. This advances the program towards regulatory filing for clinical testing.
At the time of this filing, EVAX was trading at $3.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.6M. The 52-week trading range was $2.07 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.